RecruitingNCT06350734
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Sponsor
Mayo Clinic
Enrollment
704 participants
Start Date
Oct 12, 2018
Study Type
OBSERVATIONAL
Conditions
Summary
This study evaluates the effect of bladder cancer treatment on quality of life.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This is a quality-of-life study for people who have been diagnosed with bladder cancer, asking them to complete surveys before and after treatment (surgery or radiation) to understand how different treatments affect their day-to-day life and wellbeing.
**You may be eligible if...**
- You have been diagnosed with bladder cancer confirmed by a pathology test
- Your cancer is localized (has not spread to distant organs)
- You are about to start treatment (surgery or radiation therapy)
- You are able to complete a survey in English
- You are able to provide informed consent
**You may NOT be eligible if...**
- You do not meet the inclusion criteria above
- You are unable or unwilling to complete the required surveys
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNon-Interventional Study
Non-Interventional Study
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06350734
Related Trials
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
NCT07061964134 locations
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
NCT06770582124 locations
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
NCT0700008456 locations
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NCT07097142211 locations
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
NCT067041911 location